SB 204741
Modify Date: 2024-01-14 18:25:01
SB 204741 structure
|
Common Name | SB 204741 | ||
|---|---|---|---|---|
| CAS Number | 152239-46-8 | Molecular Weight | 286.35200 | |
| Density | 1.38g/cm3 | Boiling Point | 335.9ºC at 760 mmHg | |
| Molecular Formula | C14H14N4OS | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 157ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of SB 204741SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1[1]. |
| Name | 1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea |
|---|---|
| Synonym | More Synonyms |
| Description | SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1[1]. |
|---|---|
| Related Catalog | |
| Target |
human 5-HT2B Receptor:7.1 (pKi) |
| In Vitro | The most selective 5-HT2B receptor ligand to be tested is SB 204741 with approximately 20 fold selectivity for the human 5-HT2B receptor as compared to the human 5-HT2C receptor[1]. |
| In Vivo | SB-204741 (0.25~1.0 mg/kg; i.p.) induces myocardial remodeling and dose dependently improves hemodynamic and ventricular functions following isoproterenol-induced myocardial injury[1]. SB-204741 bolsters endogenous anti-oxidant enzymes activities, improves cardiac injury markers, NO level and lipid peroxidation level and attenuates TNFα level in isoproterenol-induced myocardial remodeling in rats. SB-204741 (0.5 and 1.0 mg/kg/day) pre-treatment for 28 days significantly amplifies NO level and GSH and SOD activities and attenuates TBARS level following isoproterenol-induced myocardial remodeling. SB-204741 inhibits inflammatory protein expression, upregulates autophagy and HSPs protein expressions in isoproterenol-induced myocardial remodeling in rats. SB-204741 improves myocardial architecture in isoproterenol-induced myocardial remodeling in rats[1]. Animal Model: Rats[1] Dosage: 0.25~1.0 mg/kg Administration: I.p. Result: Induced myocardial remodeling. |
| References |
| Density | 1.38g/cm3 |
|---|---|
| Boiling Point | 335.9ºC at 760 mmHg |
| Molecular Formula | C14H14N4OS |
| Molecular Weight | 286.35200 |
| Flash Point | 157ºC |
| Exact Mass | 286.08900 |
| PSA | 87.19000 |
| LogP | 3.73320 |
| Vapour Pressure | 0.000116mmHg at 25°C |
| Index of Refraction | 1.707 |
| Storage condition | 2-8°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| RIDADR | NONH for all modes of transport |
|
Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude.
J. Neurosci. 35 , 9580-94, (2015) Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, des... |
| Tocris-1372 |
| N-(1-Methyl-1H-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea |
| Lopac-S-0693 |